Literature DB >> 9065481

Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists.

R Mukherjee1, L Jow, G E Croston, J R Paterniti.   

Abstract

We describe the cloning, characterization, and tissue distribution of the two human peroxisome proliferator activated receptor isoforms hPPARgamma2 and hPPARgamma1. In cotransfection assays the two isoforms were activated to approximately the same extent by known PPARgamma activators. Human PPARgamma binds to DNA as a heterodimer with the retinoid X receptor (RXR). This heterodimer was activated by both RXR agonists and antagonists and the addition of PPARgamma ligands with retinoids resulted in greater than additive activation. Such heterodimer-selective modulators may have a role in the treatment of PPARgamma/RXR-modulated diseases like diabetes. Northern blot analysis indicated the presence of PPARgamma in skeletal muscle, and a sensitive RNase protection assay confirmed the presence of only PPARgamma1 in muscle that was not solely due to fat contamination. However, both PPARgamma1 and PPARgamma2 RNA were detected in fat, and the ratio of PPARgamma1 to PPARgamma2 RNA varied in different individuals. The presence of tissue-specific distribution of isoforms and the variable ratio of PPARgamma1 to PPARgamma2 raised the possibility that isoform expression may be modulated in disease states like non-insulin-dependent diabetes mellitus. Interestingly, a third protected band was detected with fat RNA indicating the possible existence of a third human PPARgamma isoform.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9065481     DOI: 10.1074/jbc.272.12.8071

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  90 in total

1.  A human peripheral blood monocyte-derived subset acts as pluripotent stem cells.

Authors:  Yong Zhao; David Glesne; Eliezer Huberman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-26       Impact factor: 11.205

Review 2.  Role of nuclear receptors in blastocyst implantation.

Authors:  Y M Vasquez; F J DeMayo
Journal:  Semin Cell Dev Biol       Date:  2013-08-28       Impact factor: 7.727

3.  Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria.

Authors:  Mahmut Ilker Yilmaz; Alper Sonmez; Kayser Caglar; Deniz Engin Gok; Tayfun Eyileten; Müjdat Yenicesu; Cengizhan Acikel; Necati Bingol; Selim Kilic; Yusuf Oguz; Abdulgaffar Vural
Journal:  Endocrine       Date:  2004-12       Impact factor: 3.633

4.  PPARγ is an E3 ligase that induces the degradation of NFκB/p65.

Authors:  Yongzhong Hou; France Moreau; Kris Chadee
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

5.  Inhibitory effects of PPARγ ligands on TGF-β1-induced corneal myofibroblast transformation.

Authors:  Kye-Im Jeon; Ajit Kulkarni; Collynn F Woeller; Richard P Phipps; Patricia J Sime; Holly B Hindman; Krystel R Huxlin
Journal:  Am J Pathol       Date:  2014-03-17       Impact factor: 4.307

Review 6.  The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis.

Authors:  Hebe N Gouda; Gurdeep S Sagoo; Anne-Helen Harding; Jan Yates; Manjinder S Sandhu; Julian P T Higgins
Journal:  Am J Epidemiol       Date:  2010-02-23       Impact factor: 4.897

7.  Peroxisome proliferator-activated receptors in diabetic nephropathy.

Authors:  Shinji Kume; Takashi Uzu; Keiji Isshiki; Daisuke Koya
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

8.  The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer.

Authors:  Masahide Matsuyama; Rikio Yoshimura
Journal:  Biologics       Date:  2008-12

9.  Current understanding of the role of PPARγ in gastrointestinal cancers.

Authors:  Bing Zou; Liang Qiao; Benjamin C Y Wong
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

10.  Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells.

Authors:  Yekaterina Y Zaytseva; Xin Wang; R Chase Southard; Natalie K Wallis; Michael W Kilgore
Journal:  Mol Cancer       Date:  2008-12-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.